Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a Healthcare company (Biotechnology) with a market capitalization of $536M. The Maz Rating grades it against the other companies in its sector.
Aclaris Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.38, Aclaris Therapeutics, Inc. trades at 82.6x sales and 3.0x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $93M. It runs a gross margin of 99.8%, an operating margin of -1414.0% and a net margin of -1244.1%. It shows return on equity of -59.2%, return on invested capital of -47.2% and a free cash flow yield of -14.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 5.09. Over the past 52 weeks the share price ranged from $2.34 to $6.60, with a beta of 0.80.
Aclaris Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 14 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.